Yoon Sim Yap, Huiping Li, Qingyuan Zhang, Patrapim Sunpaweravong, Roland Ching-Yu Leung, Chayanee Samdaengpan, Chi-Feng Chung, Xiaojia Wang, Kyung Hae Jung, Hooi Lay Teh, Ling-Ming Tseng, Neville Chua, Yanling Jin, Tiffany D. Clark, Seock-Ah Im. "INAVO120 phase 3 trial: Subgroup analyses of Asian patients (pts) with
                    <i>PIK3CA</i>
                    -mutated (mut), hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.19_suppl.28